FDA Issues Guidance on Medication Guide Statements

Article

ePT--the Electronic Newsletter of Pharmaceutical Technology

The US Food and Drug Administration released a new guidance for industry, Medication Guides-Adding a Toll-Free Number for Reporting Adverse Events, on June 8, 2009.

The US Food and Drug Administration released a new guidance for industry, Medication Guides-Adding a Toll-Free Number for Reporting Adverse Events, on June 8, 2009. Applicable to drug manufacturers that must have an FDA-approved Medication Guide under the Federal Food, Drug and Cosmetics Act, the guidance requires firms to include in their guides the agency’s toll-free MedWatch phone number for reporting side effects and a statement that the number is to be used for reporting purposes only.

Manufacturers must also notify FDA that the side effects statement has been added to their Medication Guides.  The guidance takes effect July 1, 2009. FDA issued a final rule on this topic in October 2008 (see back story, FDA Requires Side Effects Statement on Labeling).

The statement in the Medication Guide must be printed verbatim as follows: “Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.” The statement must go under the guide’s section titled, “What are the possible or reasonably likely side effects of (name of drug)?”

Changes to already existing medication guides can be reported to FDA via annual reports.

In related news, FDA is posted an updated list of side effects obtained through its adverse events reporting system for the fourth quarter of 2008.

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes